Systemic Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer

Download this slideset to learn how experts approach treatment for patients with mHSPC.
Alicia K. Morgans, MD, MPH
Format: Microsoft PowerPoint (.ppt)
File Size: 1.51 MB
Released: September 10, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Astellas
Bayer HealthCare Pharmaceuticals Inc.
Myovant Sciences Ltd.
Pfizer, Inc.

Related Content

Cabozantinib plus atezolizumab suggested encouraging anticancer activity in metastatic castration-resistant prostate cancer; ESMO coverage from Clinical Care Options (CCO)

person default Eva Ciruelos, MD, PhD Karim Fizazi, MD, PhD Eric Van Cutsem, MD, PhD person default Vamsidhar Velcheti, MD Released: September 21, 2021

Download this short slideset from Clinical Care Options (CCO) the use of androgen deprivation therapy for nonmetastatic or metastatic prostate cancer

Daniel W. Lin, MD Alicia K. Morgans, MD, MPH David F. Penson, MD Released: September 20, 2021

Experts highlight key studies being presented at the upcoming 2021 ESMO Congress in this commentary from Clinical Care Options (CCO)

person default Eva Ciruelos, MD, PhD Karim Fizazi, MD, PhD Eric Van Cutsem, MD, PhD person default Vamsidhar Velcheti, MD Released: September 15, 2021

Slides from Clinical Care Options (CCO) on 2021 treatment recommendations for patients with nmCRPC.

David F. Penson, MD Released: September 10, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue